Why the study?
Does spironolactone have acceptable safety and tolerability in patients with mild to moderate chronic kidney disease?
Does spironolactone have acceptable safety and tolerability in patients with mild to moderate chronic kidney disease?
Answers are grounded in this paper and cite their sources.
Spironolactone appears well tolerated in early stage CKD, provided there is strict monitoring during the first month of treatment.
Spironolactone was well tolerated in selected patients with early stage CKD. Strict monitoring over the first month of treatment followed by standard surveillance as for ACE inhibitors and ARBs is suggested.
No takes yet. Share an insight, caveat, or question.
Edwards et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: